<DOC>
	<DOCNO>NCT01558934</DOCNO>
	<brief_summary>The primary objective study ass QTc ( interval heart rythym ) interaction effect lofexidine methadone . The secondary objective study evaluate safety tolerability lofexidine evaluate monitoring pharmacokinetics ( amount drug blood ) , vital sign ( heart rate blood pressure ) adverse event ( side effect ) co-administered methadone ; describe effect opiate withdrawal lofexidine introduce follow 50 % 100 % methadone dose reduction , require elicit withdrawal response . The investigator hypothesize agent know prolong QTc interval , combination drug create additive effect create significant safety concern . The investigator hypothesize subject able tolerate therapeutic dose lofexidine ( 0.8 mg four time daily ) methadone maintenance dose lower elicit withdrawal .</brief_summary>
	<brief_title>Pilot Study Lofexidine Methadone Pharmacodynamic Interaction Methadone Maintained Patients</brief_title>
	<detailed_description>This open-label multiple ascend dose study assess safety , tolerability , electrocardiographic effect lofexidine 6 methadone-maintained adult subject . The study include Screening Visit , Inpatient Treatment Visit , Follow-Up Visit . Subjects stable dose methadone ( 80 - 120 mg/day ) satisfy inclusion exclusion criterion eligible study . Within 21 day Screening Visit , subject report inpatient study facility begin Inpatient Treatment Visit last 10 27 day . This visit include inpatient check-in ( 1 day ) , Methadone Baseline ( 1 day ) , Initial Lofexidine Titration ( 4 day ) , 1 , 2 3 Lofexidine Plateaus ( 2 day ) , Methadone Reduction ( 11 day ) , Methadone Re-Titration Discharge ( 4 day ) . The order step subject proceed Inpatient Treatment Visit vary depend subject ' ability titrate 0.8 mg QID dose lofexidine whether experience opiate withdrawal methadone reduction . Diagrams three scenario occur lofexidine titration locate Figure 1 , 2 , 3 body protocol . During Methadone Baseline phase subject take single daily dose methadone 1 PM undergo baseline study assessment include electrocardiogram ( ECG ) monitoring blood collection methadone pharmacokinetics . The next day subject proceed Initial Lofexidine Titration phase . Subjects continue use baseline methadone dose . Lofexidine initiate 0.2 mg QID titrate daily increment 0.2 mg QID total dose 0.8 mg QID ( 3.2 mg/day ) , tolerate subject . Lofexidine dose escalate daily unless point subject meet protocol-defined dose hold criterion ( describe ) , trigger reduction dose previous high tolerate dose . Once subject titrate 0.8 mg QID dose high tolerate dose lofexidine determine , proceed 2-day Lofexidine Plateau phase continue receive methadone maintenance dose . If subject able titrate 0.8 mg QID , subject continue receive high tolerate dose equal increment ( eg , 0.2 , 0.4 , 0.6 mg QID 8AM , 1PM , 6PM , 11PM ) day plateau . If subject tolerate 0.8 mg QID lofexidine , first day receive 0.8 mg QID lofexidine accord normal dosing schedule . On second day lofexidine dose schedule modify subject receive 0.2 mg increase 1 PM lofexidine dose ( 1 mg dose ) 0.2 mg reduction subsequent lofexidine dose ( 0.6 mg dose ) 2 dos 0.8 mg ( total dose 3.2 mg/day ) . On second day Lofexidine Plateau phase , subject undergo electrocardiogram ( ECG ) monitoring blood collection methadone lofexidine pharmacokinetics . Subjects unable titrate 0.8 mg QID lofexidine dose receive full dose methadone undergo methadone dose reduction 50 % , necessary dose reduction 100 % , continue lofexidine titration add incremental 0.2 mg QID previously establish tolerate dose maximum 0.8 mg QID dose . During subsequent titration attempt lofexidine dos escalate daily unless event subject meet protocol define dose-hold criterion ( describe ) , trigger reduction dose previous high tolerate dose require Lofexidine Plateau procedures describe repeated maintain subject newly reduce methadone dose ( eg , 50 % maintenance dose , 0.8 mg QID achieve first reduction , 0 % maintenance dose 2 day follow reinstatement 25 % start dose ) . Subjects able titrate 0.8 mg QID lofexidine dose receive full dose methadone continue receive maximum lofexidine dose undergo 4 day Methadone Reduction 50 % maintenance dose evaluate lofexidine 's impact withdrawal syndrome . During Methadone Reduction ( whether subject enter experimental 4-day 50 % withdrawal phase tolerate 0.8 mg QID lofexidine dose subject continue lofexidine titration 50 % 100 % methadone reduction ) , assessment opiate withdrawal perform use Clinical Opiate Withdrawal Scale ( COWS ) Short Opiate Withdrawal Scale ( SOWS ) . Following completion Lofexidine Plateau ( repeat necessary ) Methadone Reduction , subject begin Methadone Re-Titration Discharge phase lofexidine discontinue ( except treat withdrawal symptom necessary ) methadone re-titrated start dose ( high low dose relative baseline medically indicate discretion investigator ) . Following successful methadone titration completion study assessment , subject discharge inpatient study clinic . Subjects return study clinic follow-up visit 7 day ( ±2 day ) follow clinic discharge safety follow-up adverse event collection . Subjects discharge study time unless medically unstable dose methadone . Subject may medically follow regular interval , determine investigator , subject consider sufficiently stable study discharge . Subjects withdraw consent meet one follow study termination criterion prior completion study withdrawn : 1 . Cardiovascular event include follow : 1 . Systolic blood pressure &lt; 70 mmHg &gt; 20 % screen value ; 2 . Diastolic blood pressure &lt; 40 mmHg &gt; 20 % screen value : 3 . Heart rate &lt; 40 bpm &gt; 20 % screen value ; 4 . QTc &gt; 500 msec &gt; 25 % screen value male female ; 5 . Syncope . *ECGs vital sign may repeat appropriate confirm value rule extraneous result . 2 . Serious medical problem think relate unrelated study medication . 3 . Intercurrent illness medical complication , opinion site investigator , preclude safe administration study medication . At time termination study , subject discontinue lofexidine ; however , may remain inpatient 4 day methadone maintenance dose re-titrated pre-study maintenance dose .</detailed_description>
	<mesh_term>Substance Withdrawal Syndrome</mesh_term>
	<mesh_term>Methadone</mesh_term>
	<mesh_term>Clonidine</mesh_term>
	<mesh_term>Lofexidine</mesh_term>
	<criteria>1 . Adult male and/or female , 18 60 year age ( inclusive ) 2 . Receiving methadone maintenance treatment opioid dependence stable oncedaily dose 80120 mg least 4 week prior checkin Inpatient Treatment Visit . 3 . Body mass index ≥ 18 ≤ 35 ( kg/m2 ) . 4 . Normal screen result abnormal result deem Investigator clinically insignificant . 5 . Able understand willing sign inform consent form ( ICF ) . 6 . Females practice adequate birth control nonchildbearing potential . Medically acceptable birth control method study include intrauterine device ( IUD ) ; vasectomize partner ( minimum 6 month ) ; postmenopausal ( least 2 year ) ; surgically sterile ( least 6 month ) ; double barrier ( diaphragm spermicide , condom vaginal spermicide ) ; abstinence ; implant intrauterine hormonal contraceptive use least 6 consecutive month prior study dose throughout study duration ; oral , patch inject hormonal contraceptive vaginal hormonal device ( ie , NuvaRing® ) use least 3 consecutive month prior study dose throughout study duration . 1 . Abnormal cardiovascular exam screen randomization , include follow : clinically significant abnormal electrocardiogram ( ECG ) ( eg , significant first degree atrioventricular block , second third degree heart block , clinically significant arrhythmia , QTc interval ( machine read ) great 450 msec male great 470 msec female ) * heart rate &lt; 55 bpm symptomatic bradycardia* systolic blood pressure ( SBP ) &lt; 95 mmHg symptomatic hypotension* diastolic blood pressure ( DBP ) &lt; 65 mmHg* blood pressure ( BP ) &gt; 155/95 mmHg* change orthostatic SBP , DBP , heart rate &gt; 25 % recumbent value prior history myocardial infarction ( MI ) evidence prior MI ECG* *ECGs vitals may repeat appropriate order confirm value rule extraneous result . 2 . History presence significant cardiovascular , hepatic , renal , hematological , gastrointestinal , endocrine , immunologic , psychiatric , neurologic , dermatologic disease . 3 . History presence degree chronic obstructive pulmonary disease . 4 . History suicidal ideation depression require professional intervention include counsel antidepressant medication . 5 . Positive drug ( urine ) /alcohol ( breath ) test Screening Visit checkin Inpatient Clinic Visit exclude methadone . Subjects positive test heroin benzodiazepine Screening Visit may enrol test negative checkin Inpatient Treatment Visit . Subjects positive test heroin benzodiazepine Screening Visit must sign ICF checkin Inpatient Clinic Visit . 6 . Receiving methadone pain management . 7 . Positive test human immunodeficiency virus ( HIV ) hepatitis B surface antigen ( HBsAg ) . Subjects positive test hepatitis C antibody ( HCV ) may enrol subject asymptomatic . 8 . Estimated creatinine clearance &lt; 80 mL/minute screening ( CockroftGault formula ) . 9 . AST , ALT , alkaline phosphatase &gt; 3.0 x upper limit normal screen checkin . 10 . Amylase lipase &gt; 1.5 x upper limit normal screen checkin . 11 . History hypotension . 12 . History hypersensitivity allergy clonidine clonidine analogue . 13 . Use new prescription medication within 12 day prior checkin . 14 . Use overthecounter medication , include herbal product , within 5 day prior checkin . Up 2 gram per day acetaminophen allow discretion PI/PI‟s designee . 15 . Use drug know affect QTc within 30 day prior checkin ( tobacco exclude ) . 16 . Blood donation significant blood loss within 30 day prior checkin . 17 . Plasma donation within 7 day prior checkin . 18 . Participation another clinical trial within 30 day prior checkin . 19 . Females pregnant lactating . 20 . Any condition prior therapy , , opinion Investigator , would make subject unsuitable study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>lofexidine</keyword>
	<keyword>methadone</keyword>
	<keyword>interaction</keyword>
	<keyword>pharmacodynamic</keyword>
	<keyword>ECG</keyword>
	<keyword>QTc</keyword>
</DOC>